Figure 2: TCERG1L expression influences in vitro and in vivo responses to cisplatin. (a) TCERG1L overexpression (TCERG1L) and silencing (siTCERG1L) in HeLa cells significantly reduces and enhances cisplatin cytotoxicity, respectively, compared to empty vector (EV) or non-targeting (siNT) controls. Cisplatin CC50 was 5.5mM (siTCERG1L) and 18.6mM (TCERG1L). Control conditions (EV, siNT) cisplatin CC50 was 10mM. ***P<.001; ****P<.0001 using extra sum of squares F test; n=21 from 3 independent experiments (overexpression) and n=9 from 2 independent experiments (silencing). Data are shown as the mean and standard deviation. (b) Pro-inflammatory IL-8 secretion at 100mM cisplatin was significantly reduced, or enhanced, by TCERG1L overexpression and silencing in HeLa cells compared to their respective controls. ****P<.0001 using two-tailed student t-test; n=6 or 9 from two independent experiments. Standard deviation is shown. Overexpression and silencing experiments were performed separately but shown on the same axes for comparison in a and b. RNA expression changes of TCERG1L (c) and IL-6 (d) across several mouse tissues following cisplatin exposure. Relative fold changes were calculated per organ against saline injected controls.